Claudio Rumazza
Venture Capital
Italy
Education
Work Experience
2020
Investment Committee
2020
EIC Fund Advisory Committee
2022
2020
Chairman Strategic Committee
2020
Bio4Dreams is a Life Sciences incubator and investment holding that offers tailor-made support programs together with expertise specific to Life Sciences and a multidisciplinary result-driven team, focused on providing structure and stability to the first steps of newly born startups
2010 - 2020
Partner
2010 - 2020
Innogest SGR is an indipendent Venture Capital firm with offices in Milan, Turin, San Francisco and Geneva investing in highly innovative and fast growing companies.
2017 - 2019
Board Director
2017 - 2019
Medlumics is developing a novel catheter for the treatment of atrial fibrillation through pulmonay vein ablation, using OCT (Optical Coherence Tomography) for a real-time, direct lesion assessment improving the efficacy of the treatment thanks to the creation of a more controlled continuous lesion.
2016 - 2019
Investor, Board Observer
2016 - 2019
Anaconda Biomed is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies based on a novel design combining the advantages of direct aspiration catheters and stent retrievers.
2015 - 2019
Investor, Board observer
2015 - 2019
Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis
2015 - 2019
Board Director
2015 - 2019
Newronika is a medical device company developing an adaptive deep brain stimulation device for movement disorders and a transcranial direct current stimulation system for depression, pain and neuro rehabilitation
2015 - 2019
Investor, Board observer
2015 - 2019
Angiodroid develops and markets the only automatic injector of carbon dioxide as a contrast medium in angiography.
2013 - 2019
Board Director
2013 - 2019
EryDel is specialized in the development of drugs and diagnostics delivered through patient's red blood cells by using a proprietary medical device technology. The first product based on Erydel's platform is EryDex, a treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive disorder with onset in the first years of life.